Gender considerations in hypertension pathophysiology and treatment

American Journal of Medicine

Volumn 101, Issue 3 A, 1996, Pages 10S-21S

  Hanes, Donna S ^a   Weir, Matthew R ^a   Sowers, James R ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; HYDROCHLOROTHIAZIDE; SEX HORMONE;

AGING; ANTIHYPERTENSIVE THERAPY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ESTROGEN BLOOD LEVEL; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; HUMAN; HYPERTENSION; OSTEOPOROSIS; PRIORITY JOURNAL; RENOVASCULAR DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TREATMENT PLANNING; FEMALE; HEMODYNAMICS; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; SEXUAL DEVELOPMENT;

CORONARY DISEASE; FEMALE; GONADAL STEROID HORMONES; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; MALE; RISK FACTORS; SEX CHARACTERISTICS;

EID: 0030606971     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00264-1     Document Type: Article

References (90)

1. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population - data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26:60-69.
2. Douglas PS, Ginsburg GS. The evaluation of chest pain in women. N Engl J Med. 1996;334:1311-1315.
3. Kannel WB. Cardioprotection and antihypertensive therapy. The key importance of addressing the associated coronary risk factors (the Framingham experience). Am J Cardiol. 1996;77(suppl):6B-11B.
4. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1993;153:154-181.
5. Walsh MF, Dominguez LJ, Sowers JR. Metabolic abnormalities in cardiac ischemia. Cardiology Clinics, 1995;13:529-538.
6. National Center for Health Statistics. Vital statistics of the United States 1986, II: Mortality, A and B. Washington, D.C., U.S. Department of Health and Human Services; 1988; Publications 88-1122 and 88-1113.
7. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861-1867.
8. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes. A 26-year follow-up of the Framingham population. Am Heart J. 1986 1:383-390.
9. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 1993;153:2209-2216.
10. Anastos K, Charney P, Charon RA, et al. Hypertension in women: what is really known? The Women's Caucus, Working Group on Women's Health of the Society of General Internal Medicine. Ann Intern Med. 1991;115:287-293.
11. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham study. Am Heart J. 1987;114:413-419.
12. Albert C. Sex differences in cardiac arrest survivors. Circulation. 1996;93:1170-1176.
13. Bittner V. Hypertension in women. Curr Opin Nephrol Hypertens. 1995;4:A204-A207.
14. Lewis CE, Grandits GA, Flack J, McDonald R, Elmer PJ. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Arch Intern Med. 1996;156:377-385.
15. Walsh JME, Grady D. The treatment of hyperlipidemia in women. JAMA. 1995;274:1152-1158.
16. Williams PT. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners. N Engl J Med. 1996;334:1298-1303.
17. Messerli VH, Garavaglia GE, Schmieder R. Disparate cardiovascular findings in men and women with essential hypertension. Ann Intern Med. 1987;107:158-163.
18. Saab PG. Cardiovascular and neuroendocrine responses to challenge in males and females. In: Schneiderman N, Weiss SM, Kaufman PG, eds. Handbook of Research Methods in Cardiovascular Behavioral Medicine. New York: Plenum Press; 1989:453-481.
19. Stoney CM, Davis MC, Matthews KA. Sex differences in physiological responses to stress and coronary heart disease: a causal link? Psychophysiology. 1987;24:127-131.
20. Verdecchia P, Schillaci G, Borgioni C, et al. Gender, day-night blood pressure changes, and left ventricular mass in essential hypertension. Am J Hypertens. 1995;8:193-196.
21. Verdecchia P, Schillaci C, Gatteschi I, et al. Blunted nocturnal fall in blood pressure in hypertensive women with future cardiovascular morbid events. Circulation. 1993;88:986-992.
22. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 1994;121:936-941.
23. Sullivan JM, Vander Zwaag R, Lemp GF, et al. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med. 1988;108:358-363.
24. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten year follow-up from the nurses' health study. N Engl J Med. 1991;325:756-762.
25. Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. Am J Cardiol. 1992;69:176-178.
26. Walsh BW, Schiff I, Rosner B, Grienberg L, Ravnikar V, Sacks F. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196-1204.
27. Bush TL, Barrett-Conner E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75:1182-1189.
28. Colburn P, Buonassisi V. Estrogen binding sites in endothelial cell cultures. Science. 1978;210:817-819.
29. McGill HC Jr, Sheridan PJ. Nuclear uptake of sex steroid hormones in the cardiovascular system of the baboon. Circ Res. 1981;48:238-244.
30. Horwitz KB, Horwitz LD. Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. J Clin Invest. 1982;69:750-758.
31. 2+ currents in vascular smooth muscle. Am J Physiol. 1994;193:C975-C980.
32. Simpson LL, Zhang F, Standley PR, Ram JL, Weir MR, Sowers JR. Role of calcium in vascular smooth muscle proliferation: antiproliferative effects of verapamil enantiomers - independence from calcium channel blockage. J Vasc Med Biol. 1994;5:46-53.
33. Sullivan TR, Karas RH, Aronovitz M, et al. Estrogen inhibits the response to injury in a mouse carotid artery model. J Clin Invest 1995;96:2482-2488.
34. Hayashi T, Fukuto JM, Ignarro LJ, Chaudharc G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Nat Acad Sci USA. 1992;89:11259-11263.
35. Conrad KP, Jaffe GM, Kruszyna R, et al. Identification of increased nitric oxide biosynthesis during pregnancy in rats. FASEB J. 1993;7:566-571.
36. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA. 1994;91:5212-5216.
37. Hayashi T, Yamada K, Esaki T, et al. Estrogen increases endothelial nitric oxide by a receptor mediated system. Biochem Biophys Res Comm. 1995;214:847-855.
38. Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for MRFIT. Am Heart J. 1986;112:825-836.
39. Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension. 1989;13(suppl 1):12-12.
40. Munetta S, Murakami E, Hiwada K. Gender difference in blood pressure regulation in essential hypertension. Hypertens Res. 1994;17:71-78.
41. Blood pressure levels in persons 18-74 years of age in 1976-80, and trends in blood pressure from 1960 to 1980 in the United States. National Health Survey, Series 11,234, DHHS Publication (PHS) 86-1684.
42. Boyle E Jr. Biological patterns in hypertension by race, sex, body weight, and skin color. JAMA. 1970;213:1637.
43. Turner ST, Weidman WH, Michels VV, et al. Distribution of sodium-lithium counter-transport and blood pressure in Caucasians who live to 89 years of age. Hypertension. 1989;13:378-391.
44. Staessen J, Bulpitt SJ, Fagard R, Lijnen FR, Amery A. The influence of menopause on blood pressure. J Hum Hypertens. 1989;3:427-433.
45. Mills PJ, Nelesen RA, Ziegler MG, et al. Menstrual cycle effects on catecholamine and cardiovascular responses to acute stress in black but not white normotensive women. (1996, submitted)
46. Falkner B, Franke M, Dugger E, Petrov L, Kushner H. Sex hormone status, insulin resistance, and blood pressure in African Americans. (Abstr.) Hypertension. 1995;25:8.
47. Schwartz J, Freeman R, Frishman W. Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women. J Clin Pharmacol. 1995;35:1-16.
48. The writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions trial. JAMA. 1995;273:199-208.
49. Knopp RH, Zhu X, Bonet B. Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women (review). Atherosclerosis. 1994;110:S83-S91.
50. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population: sixteen-year follow-up study. Diabetes Care. 1990;13:631-654.
51. USRDS 1995 Annual Data Report. Incidence and causes of treated ESRD. Am J Kidney Dis. 1995;26:S39-S50.
52. Barrett-Connor E, Wingard DL. Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study. Am J Epidemiol. 1983;118:489-496.
53. Stout RW. Insulin and atheroma: 20 year perspective. Diabetes Care. 1990;13:631-654.
54. Sowers JR. Insulin resistance, hyperinsulinemia, dyslipidemia, hypertension and accelerated atherosclerosis. J Clin Pharmacol. 1992;32:529-535.
55. Donahue RP, Barrett-Connor E, Orchard TJ, Gutai JP. Endogenous insulin and sex hormones in atherosclerosis and coronary heart disease. Arteriosclerosis. 1988;8:544-548.
56. Baylis C, Samsell L, Racusen L, Gladfelter W. Hypothalamic lesions induce obesity and sex-dependent glomerular damage and increases in blood pressure in rats. Hypertension. 1996;27:926-932.
57. Ashton N, Balment RJ. Sexual dimorphism in renal function and hormonal status of New Zealand genetically hypertensive rats. Acta Endocrinol. 1991;124:91-97.
58. Crofton JT, Share L, Brooks DP. Gonadectomy abolishes the sexual dimorphism in DOC-salt hypertension in the rat. Clin Exp Hypertens A. 1989;11:1249-1261.
59. Goldberg RJ, Larson M, Levy D. Factors associated with survival to 75 years of age in middle-aged men and women: the Framingham Study. Arch Intern Med. 1996;156:505-509.
60. Hypertension Detection and Follow-up Program Cooperative Group. Five year findings of the hypertension detection and follow-up program II. Mortality by race, sex, and age. JAMA. 1979;242:2572-2577.
61. Schnall P, Alderman MH, Kern R. An analysis of the HDFP trial. Evidence of adverse effects of antihypertensive therapy on white women with moderate to severe hypertension. NY Stat J Med. 1984;84:299-301.
62. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principle results. Br Med J. 1985;291:197-204.
63. Management Committee of the Australian Therapeutic Trial in Mild Hypertension. The Australian Committee of the Australian Therapeutic Trial of Mild Hypertension. Lancet. 1980;i:1261-1267.
64. Management Committee of the Australian Therapeutic Trial of Mild Hypertension in the Elderly. Med J Aust. 1981;2:398-402.
65. Lerner DJ, Kannel WB. Patterns of coronary disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986;111:383-390.
66. Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA. 1991;265:3255-3264.
67. The Systolic Hypertension in the Elderly Program Cooperative Research Group. Implications of the systolic hypertension in the elderly program. Hypertension. 1993;21:335-343.
68. Boehringer K, Weidmann P, Mordasini R, Schiffl H, Bachmann C, Riesen W. Menopause-dependent plasma lipoprotein alterations in diuretic-treated women. Ann Intern Med. 1982;97:206-209.
69. Perloff D. Hypertension in women. In: Douglas PS, ed. Heart Disease in Women. Philadelphia: FA Davis, 1989.
70. Neutel JM. Metabolic manifestations of low-dose diuretics. Am J Med. 1996;101(suppl 3A):71-82.
71. Hiedrich FE, Stergachis A, Gross KM. Diuretic drug use and the risk for hip fracture. Ann Intern Med. 1991;115:1-6.
72. Morton DJ, Barrett-Connor EL, Edelstein SL. Thiazides and bone mineral density in elderly men and women. Am J Epidemiol. 1994;139:1107-1115.
73. Wasnich R, Davis J, Ross P, Vogel J. Effect of thiazide on rates of bone mineral loss: a longitudinal study. Br Med J. 1991;302:18.
74. Ray WA. Thiazide diuretics and osteoporosis: time for a clinical trial. Ann Intern Med. 1991;115:64-65.
75. Jones G, Nguyen T, Sambrook PN, Eisman JA. Thiazide diuretics and fractures: can meta-analysis help? J Bone Min Res. 1995;10:106-111.
76. Marchand X, Marchand C, de Pompignan X, et al. Diuretic thiazide and prevention of hip fracture in hypertensive postmenopausal women. Am J Hypertens. 1996;9:7A.
77. Chen Z, Vaughn DA, Fanestil DD. Influence of gender on renal thiazide diuretic receptor density and response. J Am Soc Nephrol. 1994;5:1112-1119.
78. Beta Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA. 1982;247:1707-1714.
79. Furberg CD, Byington RP. What do subgroup analysis reveal about differential response to beta-blocker therapy? The beta-blocker heart attack trial experience. Circulation. 1983;67:I98-I101.
80. Rodda BE. The timolol myocardial infarction study: an evaluation of selected variables. Circulation. 1983;67:I101-I105.
81. Petitti N, Etgen A. Alpha-1 adrenoreceptor augmentation of beta-stimulated cAMP formation is enhanced by estrogen and reduced by progesterone in rat hypothalamic slices. J Neurosci. 1990;10:2842-2849.
82. Carlberg KA, Fregly MJ. Catecholamine excretion and beta-adrenergic responsiveness in estrogen-treated rats. Pharmacology. 1986;32:147-156.
83. Packer M, Bristow MR, Cohn J, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
84. Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. Hypertension. 1995;25:124-130.
85. Dzau VJ, Ellison KE, Brody T. A comparative study of the distribution of renin and angiotensinogen messenger ribonucleic acids in rat and mouse tissues. Endocrinology. 1987;120:2334-2338.
86. Seltzer A, Pinto JE, Vigione PN, et al. Estrogens regulate angiotensin-converting enzyme and angiotensin receptors in female rat anterior pituitary. Neuroendocrinology. 1992;55:460-467.
87. Brosnihan KB, Moriguchi A, Nakamoto H, Dean RH, Ganten D, Ferrario CM. Estrogen augments the contribution of nitric oxide to blood pressure regulation in transgenic hypertensive rats expressing the mouse Ren-2 gene. Am J Hypertens. 1994;7:576-582.
88. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27:523-528.
89. Kloner RA, Sowers JR, DiBona GF, Gaffney M, Wein M, for the Amlodipine Cardiovascular Community Trial Study Group (ACCT Study Group ). Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol. 1996;77:713-722.
90. Rossouw JE, Finnegan LP, Harlan WR, Pinn VW, Clifford C, McGowan JA. The evolution of the Women's Health Initiative: perspectives from the NIH. J Am Med Women's Assoc. 1995;50:50-55.